Equillium Inc
Company Profile
Business description
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Contact
2223 Avenida De La Playa
Suite 105
La JollaCA92037
USAT: +1 858 240-1200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
45
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,175.10 | 26.20 | 0.32% |
| CAC 40 | 8,094.20 | 77.27 | -0.95% |
| DAX 40 | 22,999.15 | 288.91 | -1.24% |
| Dow JONES (US) | 41,953.32 | 11.31 | -0.03% |
| FTSE 100 | 8,701.99 | 4.67 | -0.05% |
| HKSE | 23,733.02 | 486.93 | -2.01% |
| NASDAQ | 17,691.63 | 59.16 | -0.33% |
| Nikkei 225 | 37,920.79 | 168.91 | 0.45% |
| NZX 50 Index | 12,113.54 | 58.82 | 0.49% |
| S&P 500 | 5,662.89 | 12.40 | -0.22% |
| S&P/ASX 200 | 7,948.00 | 29.10 | 0.37% |
| SSE Composite Index | 3,376.96 | 31.99 | -0.94% |